# Quantifying societal burden of radiation-induced small bowel toxicity in patients with rectal cancer

## TL;DR

This study evaluates how new radiation therapies for rectal cancer improve quality of life and reduce costs by lowering small bowel toxicity.

## Contribution

The study quantifies the societal burden of radiation-induced small bowel toxicity and shows cost-savings and quality-of-life improvements with newer radiotherapy techniques.

## Key findings

- IMRT/IGRT improves quality of life by 0.11 QALYs compared to 3D-CRT.
- IMRT results in 0.05 QALYs improvement over 3D-CRT.
- IMRT/IGRT saves €3,820 per patient compared to 3D-CRT.

## Abstract

Advancements in rectal cancer (RC) treatment not only led to an increase in lives saved but also improved quality of life (QoL). Notwithstanding these benefits, RC treatment comes at the price of gastrointestinal morbidity in many patients. Health economic modelling poses an opportunity to explore the societal burden of such side-effects. This study aims to quantify radiation-induced late small bowel (SB) toxicity in survivors of RC for Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity Modulated Radiation Therapy (IMRT) and Intensity Modulated Radiation Therapy – Image Guided Radiation Therapy (IMRT/IGRT).

Materials and A model-based health economic evaluation was performed. The theoretical cohort consists of a case-mix of survivors of RC aged 25-99 years according to Belgian age-specific incidence rates. A societal perspective was adopted. The base case analysis was complemented with one-way deterministic analyses, deterministic scenario analyses and probabilistic sensitivity analysis (1,000 iterations). Results were presented as mean lifetime incremental cost (€) and utility (QALYs) per patient.

The analyses showed that the use of innovative radiotherapy (RT) improves lifetime QoL in survivors of RC by 0.11 QALYs and 0.05 QALYs by preferring IMRT/IGRT and IMRT over 3D-CRT, respectively. The use of IMRT/IGRT and IMRT results in an incremental cost-saving of €3,820 and €1,863 per patient, solely by radiation-induced SB toxicity, compared to 3D-CRT.

It is important to consider late toxicity effects in decisions regarding investments and reimbursement as our analysis highlighted the potential long-term cost-savings and improved QoL of novel RT techniques in patients with rectal cancer.